Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Shire Plc Ads (SHPG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,274,368
  • Shares Outstanding, K 300,430
  • Annual Sales, $ 11,397 M
  • Annual Income, $ 327,400 K
  • 36-Month Beta 1.60
  • Price/Sales 3.81
  • Price/Cash Flow 8.83
  • Price/Book 1.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
137.17 +7.44%
on 11/13/17
150.44 -2.04%
on 11/16/17
-4.68 (-3.08%)
since 10/17/17
3-Month
137.17 +7.44%
on 11/13/17
162.64 -9.39%
on 09/12/17
-0.58 (-0.39%)
since 08/17/17
52-Week
137.17 +7.44%
on 11/13/17
192.15 -23.30%
on 05/18/17
-32.86 (-18.23%)
since 11/17/16

Most Recent Stories

More News
Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease

Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.

LGND : 140.31 (-0.99%)
RARE : 48.11 (-0.23%)
BMRN : 82.88 (+0.39%)
SHPG : 147.37 (+1.89%)
Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval

Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with...

NVO : 50.91 (+0.81%)
SHPG : 147.37 (+1.89%)
ABBV : 93.61 (-0.91%)
RHHBY : 29.1000 (+0.71%)
Shire Gets Positive CHMP Opinion for Hemophilia A Drug

Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

CORT : 18.39 (-3.46%)
LGND : 140.31 (-0.99%)
SHPG : 147.37 (+1.89%)
RHHBY : 29.1000 (+0.71%)
Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology

Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology

SHPG : 147.37 (+1.89%)
Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen(TM) Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation...

BXLT : 46.02 (-0.39%)
XBIO : 2.34 (-3.31%)
SHPG : 147.37 (+1.89%)
OPK : 4.94 (+1.44%)
Earnings Review and Free Research Report: Eli Lilly's Adjusted EPS Increased 19%

Research Desk Line-up: Shire Post Earnings Coverage

LLY : 82.89 (-0.66%)
SHPG : 147.37 (+1.89%)
Allergan (AGN) Tops Q3 Earnings Estimates, Tweaks 2017 View

Allergan (AGN) beat expectations for earnings while delivering in-line revenues in Q3. While the company slightly lowered its sales guidance, it raised the upper end of the earnings guidance.

AGN : 174.88 (+0.04%)
SHPG : 147.37 (+1.89%)
TEVA : 13.84 (+8.21%)
SGYP : 1.95 (-2.50%)
Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation...

XBIO : 2.34 (-3.31%)
SHPG : 147.37 (+1.89%)
NVS : 83.98 (+1.16%)
OPK : 4.94 (+1.44%)
Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong

Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.

EXAS : 58.87 (+0.63%)
ILMN : 209.02 (+0.24%)
EXEL : 26.38 (+2.13%)
SHPG : 147.37 (+1.89%)
Shire PLC to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / October 27, 2017 / Shire PLC (OTC PINK: SHPGF) will be discussing their earnings results in their Q3 Earnings Call to be held on October 27, 2017 at 9:00 AM Eastern Time.

SHPG : 147.37 (+1.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)

See More

Key Turning Points

2nd Resistance Point 149.51
1st Resistance Point 148.44
Last Price 147.37
1st Support Level 145.73
2nd Support Level 144.09

See More

52-Week High 192.15
Fibonacci 61.8% 171.15
Fibonacci 50% 164.66
Fibonacci 38.2% 158.17
Last Price 147.37
52-Week Low 137.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart